|Strain Name||C57BL/6-Pdcd1tm1(hPDCD1)Cd137tm1(hCD137)/Bcgen||Common Name||B-hPD-1/h4-1BB mice|
|Catalog number (Males)||BDM001M||Catalog number (Females)||BDM001F|
PD-1(Programmed death-1) ；
TNFRSF9(TNF receptor superfamily member 9, also known as 4-1BB
mRNA expression analysis
Fig 1. RT-PCR analysis of the B-hPD-1/h4-1BB humanized mice.
The splenocytes of the B-hPD-1/h4-1BB homozygous mice showed expression of human PD-1 and 4-1BB mRNA but not mouse PD-1 and 4-1BB mRNA.
Protein expression analysis
Fig 2.Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/h4-1BB mice were analyzed by flow cytometry.
Mouse 4-1BB+ T cells were detected in the WT C57BL/6 mice, while human 4-1BB+ T cells were detected in the homozygous B-hPD-1/h4-1BB mice.
Fig 3.Splenocytes from both wild type (WT) C57BL/6 and homozygous B-hPD-1/h4-1BB mice were analyzed by flow cytometry.
Mouse PD-1+ T cells were detected in the WT C57BL/6 mice, while human PD-1+ T cells were detected in the homozygous B-hPD-1/h4-1BB mice.
Combination therapy of PD-1 (Keytruda) mAb and 4-1BB antibody (Urelumab Analog) (MC38 cell line)
Fig 4. Murine colon cancer MC38 cells were
subcutaneously implanted into homozygous B-hPD-1/h4-1BB mice.
Mice were divided into control and treatment grouped
(n=5) when the tumor size was approximately 150 ± 50mm3 (n=6). Anti-hPD-1 antibody and anti-h4-1BB antibody
significantly inhibited tumor growth in the homozygous B-hPD-1/h4-1BB mice, suggesting that B-hPD-1/h4-1BB mouse model is an effective tool for in vivo efficacy evaluation of hPD-1 and h4-1BB antibody
combination therapy. Theaverage±SEM of tumor sizes are shown in the figure.